Isolation happens everywhere, every day.
Every day, in every transplant unit, patients who are clinically stable stay behind a closed door because the precautions that protect them also confine them. Weeks in one room. Visits through glass. Diagnostics postponed because the corridor is a risk.
And now we know what it costs.
3–5 weeks
In one room after allogeneic stem cell transplantation. Median 26 days, often longer.
Increased mortality
Isolation drives depression. Depression nearly doubles post-transplant mortality (HR 1.81, HCT-CI).
20M → 35M
New cancer cases per year by 2050 (+77%). Allogeneic transplants at an all-time high. Every one of these patients faces weeks of protective isolation.
Isolation is daily reality in hematology, transplantation, burns and pediatric oncology. Patients need protection. Whether protection has to mean standing still is the open question.
In use since October 2024.
MOBY® has been in clinical use at Charité – Universitätsmedizin Berlin since October 2024, on ward 39i of the Department of Paediatric Oncology and Haematology, Campus Virchow-Klinikum.
A prospective single-center cohort study at Charité is investigating the effect of MOBY on quality of life in pediatric patients with severe immunosuppression. It follows children undergoing allogeneic or autologous stem cell transplantation or high-dose chemotherapy who use MOBY during their stay.
The primary outcome is quality of life, assessed with the KINDL questionnaire and structured interviews before the first use and after four to six uses.
Secondary outcomes include the day of first mobilization, episodes of febrile neutropenia, duration of parenteral nutrition, readmission within three months, and post-traumatic stress symptoms at three months.
What the care team observed
“We want MOBY to be available wherever a child needs a transplant. For our patients, it is a real and lasting improvement in their care.”
“I hope that the use of MOBY for immunocompromised children with cancer will be an important step towards breaking the burdening isolation of our patients.”
The clinical study is not yet published.
We do not publish outcome figures before they have been through peer review. A first abstract from the Charité pilot has been submitted for conference presentation.
What comes next.
An investigator-initiated multicenter study is in planning. A pilot study in the United States is being drafted.
Regulatory status
CE-marked medical device under EU MDR 2017/745.
In active dialogue with the U.S. FDA. Not available for sale in the United States.
Partners
